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Mapacalcine is a small homodimeric protein of 19 kDa with 9 disulﬁde bridges extracted from the Cliona
vastiﬁca sponge (Red Sea). It selectively blocks a calcium current insensitive to most calcium blockers.
Speciﬁc receptors for mapacalcine have been described in a variety of tissues such as brain, smooth
muscle, liver, and kidney. Previous works achieved on hepatocytes and nervous cells demonstrated that
this protein selectively blocks a calcium inﬂux triggered by an ischemia/reperfusion (I/R) shock and ef-
ﬁciently protects cells from death after I/R. The aim of this work was to produce the recombinant ma-
pacalcine in the yeast Pichia pastoris. Mass spectrometry, light scattering analysis and biological char-
acterization demonstrated that the recombinant mapacalcine obtained was a monomeric form with
4 disulﬁde bridges which retains the biological activity of the natural protein.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Marine sponges represent a source of molecules with ther-
apeutic interests [1–4]. Limiting the extent of tissue damages after
I/R injury is crucial for the success of organ functionality recovery.
Once the blood ﬂow restored, calcium homeostasis is completely
disrupted. High levels of calcium activate biological events leading
to cell death. Mechanisms underlying I/R injury are not yet clearly
understood [5,6] and no treatment ensures a good recovery of
organ functions after I/R damages. Mapacalcine is a homodimeric
protein (MW 19 kDa; P86916), produced by a marine sponge
(Cliona vastiﬁca) [7]. Receptors for this protein have been detected
in intestinal smooth muscle, brain, kidney, and liver [7–11]. Studies
conducted on cultured hepatocytes demonstrated that mapa-
calcine inhibited a calcium inﬂux triggered by I/R without affecting
cell viability [10]. On mouse neurons, mapacalcine inhibited a
calcium inﬂux triggered by oxygen glucose deprivation (OGD),B.V. This is an open access article u
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tributed equally to this work.leading to neuron survival [12]. Mapacalcine and its receptor re-
present a starting point toward drug discovery for cell protection
against I/R damages, and toward the understanding of a possible
mechanism leading to cell death after an I/R shock. Further in-
vestigations to determine the minimal domain responsible for
protein activity, together with the necessity to generate mutants,
will require a stable source of protein. We describe here the pro-
duction and puriﬁcation of a monomeric recombinant form of
mapacalcine from Pichia pastoris retaining the properties of nat-
ural mapacalcine.2. Materials and methods
2.1. Production of recombinant 9HIS-mapacalcine in Pichia pastoris
A 270 nucleotide sequence deduced from the peptidic sequence
[7] was designed according to the yeast codon usage for the pro-
duction of a mapacalcine recombinant form (Fig. 1A) in P. pastoris
X33 strain. The mapacalcine synthetic gene (Euroﬁns MWG/oper-
on, USA) was cloned into a modiﬁed pPICZα vector carrying a
9 Histidine tag, a polyN spacer and the enterokinase (EK) and TEV
protease cleavage sites fused to the N-terminal part of the secreted
protein (Fig. 1B). The expression plasmid was linearized with thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Synthetic gene construction of mapacalcine from its aminoacid sequence. A:
Mapacalcine monomer (89 aminoacids) and its deduced synthetic gene sequence
(270 nucleotides). B: Map of the expressed 9HIS-mapacalcine cassette inserted in
Pichia pastoris genome.
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The transformants were ﬁrst selected on YPD-agar plates con-
taining 0.2 mg/mL zeocin. Then, transformants carrying the high-
est number of integrated expression cassettes coupled with zeocin
resistance were selected on YPD-agar plates by increasing the
zeocin concentration up to 8 mg/mL.
Protein expression was assayed with several transformants.
They were grown at 30 °C in 25 mL BMGH (100 mM potassium
phosphate pH 6.0, 1.34% YNB, 0.4 mg biotin, 1% glycerol) until cul-
ture OD600¼2. Cells were harvested, then expression induced in
50 mL BMMH (100 mM potassium phosphate pH 6.0, 1.34% YNB,
0.4 mg biotin, 0.5% methanol) during 5–7 days at 30 °C, with ad-
dition of methanol (0.5% ﬁnal concentration) every day. The se-
creted recombinant mapacalcine was detected by Western blot
(WB) analysis with an anti His-tag antibody. The production was
then scaled up in a 2 L fermentor with the transformant selected
for best production of the recombinant protein. For convenience
we call 9HIS-mapacalcine the recombinant ELWSPSY-9HIS-polyN-
EK-TEV-mapacalcine obtained after secretion (see sequence in
Fig. 1).2.2. Large scale expression of recombinant 9HIS-mapacalcine.
Growth media were purchased from Becton Dickinson (Le
Pont-de-Claix, France), buffers for chromatographic runs, and re-
agents were prepared using chemicals of analytical grade from
Sigma-Aldrich (Saint-Quentin-Fallavier, France).
Transformed P. pastoris cells were grown in shake ﬂasks con-
taining 100 mL of buffered minimal glycerol BMGH with
150 mg/mL zeocin until optical density of 4–6. The culture was
inoculated in 2 L of BMGH in BIOSTAT
s
Bplus laboratory fermentor
(Sartorius-Stedim, Germany). The temperature and pH were
maintained at 30 °C and 6.0, respectively. Dissolved oxygen levels
were maintained at 15% saturation by regulating aeration and
agitation in a cascading system. After complete consumption of
glycerol in the medium corresponding to 24 h batch growth phase,
a methanol fed-batch phase was initiated by adding methanol
every 8 h to a ﬁnal concentration of 0.6%. The frequency of the
methanol addition was calculated to maintain the dissolved oxy-
gen level around 15% during the induction phase. After 120 h of
induction, the culture was harvested. The cell-free broth pH was
adjusted to 7.4 and the mixture was ﬁltered on 0.45 mm cellulose
acetate membrane (Sartorius-Stedim) and frozen at 80 °C.2.3. Puriﬁcation of recombinant 9HIS-mapacalcine.
IMAC (Ni-NTA) puriﬁcation experiments were optimized on
HisTrap FF crude 1 mL pre-packed column (GE Healthcare, Swe-
den). The HisTrap™excel 5 mL ready-to-use IMAC columns were
used for the higher scale puriﬁcation. The Ni-NTA column was
equilibrated with 50 mM Tris–HCl pH 7.4, 500 mM NaCl. The cul-
ture medium was loaded onto the column. Elution was carried out
using 50 mM Tris–HCl pH 7.4, 500 mM NaCl, 500 mM imidazole.
Binding and elution were performed at a ﬂow rate of 3 mL/min.
The eluted fraction was dialyzed (Spectrapor 6 membrane MW
cutoff 3500) against a buffer containing 50 mM Tris–HCl, pH 7.4,
150 mM ammonium acetate, lyophilized and re-suspended in
5 mL of water before being loaded on a HiLoad 16/600 Superdex
75 pg size exclusion chromatography column (SEC), previously
calibrated with a gel ﬁltration markers kit, 6500–66,000 Da. (Sig-
ma-Aldrich). Elution was achieved with the dialysis buffer at 1 mL/
min and monitored by A280 nm recording.
Fraction P1 obtained from SEC was submitted to a reverse phase
chromatography (Merck, LiChrospher
s
100 RP-8, 10250 mM,
10 mm). The column was equilibrated with H2O containing 0.1 %
TFA, and eluted at 3 mL/min with a gradient of acetonitrile (0.08%
TFA) from 0% to 60% during 40 min. Elution was monitored by
A280 nm recording.
2.4. Enzymatic removal of the ELWSPSY-9HIS-polyN peptide.
6HIS-TEV protease (in-house produced) or EK (Sigma, Saint-
Quentin-Fallavier, France) was used to remove the ELWSPSY-9HIS-
polyN peptidic part of recombinant mapacalcine. For TEV protease
cleavage, 9HIS-mapacalcine (10 mg) was incubated overnight at
room temperature with 1 mg of enzyme in 50 mM Tris–HCl pH 7.4,
0.5 M urea and 0.25 mM 2-mercaptoethanol. For EK cleavage, en-
zyme (1 mg) and 9HIS-mapacalcine (10 mg) were incubated
overnight at 30 °C in 100 mM Tris–HCl pH 7.4, 1 M urea, 2 mM
CaCl2 and 100 mM NaCl. The reaction mixture was loaded on an
IMAC column (Ni-NTA) of 1 mL equilibrated with 50 mM Tris–HCl
pH 7.4, 2 mM imidazole. The non-retained material supposed to
contain the ELWSPSY-9HIS-polyN free recombinant mapacalcine
was collected. The material retained on the column was eluted
with the equilibration buffer supplemented with 500 mM imida-
zole. Fractions were analyzed by SDS PAGE and WB.
2.5. SDS PAGE and WB analyses.
SDS PAGE analyses were performed on 4–20% gels stained with
colloidal Coomassie blue (BioRad). For WB, proteins separated on
SDS PAGE were transferred during 1 h on a PVDF membrane
(Immobilon P, Millipore), blocked during 1 h in PBS containing
0.1% Tween 20 (PBST), 2.5% BSA (PBST/BSA) and probed (2 h at
room temperature or overnight at 4 °C) with an anti-penta-HIS
antibody (Qiagen) at 1/3000 dilution in PBST/BSA. The blot was
washed 6 times during 5 min with PBST, then incubated for 2 h at
room temperature with an anti-mouse HRP conjugated secondary
antibody (BioRad) at 1/3000 dilution in PBST/BSA. After 6 washes
in PBST, the blot was revealed using the ECL system (Luminata
s
forte, Millipore).
2.6. Biological validation of recombinant mapacalcine.
Electrophysiological current recording, Oxygen Glucose Depri-
vation (OGD) and cell calcium imaging on mouse cortical neurons
were achieved as described in [12] Controls were performed with
the buffer in which proteins were dissolved.
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Reduction of disulﬁde bonds (1 h at 55 °C) was achieved with
50 mM Dithiothreitol (DTT) in 10 mM ammonium acetate and al-
kylation (1 h at room temperature into the dark) with iodoaceta-
mide (IAA) at 100 mM in 10 mM ammonium acetate (ﬁnal con-
centrations). MALDI-MS analyses were carried out with a Ultraﬂex
III mass spectrometer (Bruker) using sinapinic acid (Sigma-Aldrich)
as a matrix (10 mg/mL solution in 50% acetonitrile/0.1% TFA) and a
mixture of three proteins (Insulin [MþH]þaverage¼5734.52 Da, Cy-
tochrome C [MþH]þaverage¼12,360.97 Da, Myoglobin [MþH]þaverage
¼16,952.31 Da) for external calibration. ESI-MS analyses were car-
ried out using a Q-TOF Micro mass spectrometer (Waters). Accurate
mass analysis was obtained by means of multiply charged ions of
recombinant mapacalcine with MaxEnt (Waters) used as deconvo-
lution software.
2.8. Light scattering analysis
A solution of recombinant mapacalcine (5 mg/mL) in 50 mM
Tris–HCl pH 7.4, 150 mM ammonium acetate was submitted to
light scattering analysis (LSA). The estimated molecular weight is
expressed as mean7standard deviation.3. Results
3.1. Expression of 9HIS-mapacalcine in Pichia pastoris.
In large scale experiments, no expression was observed before
addition of methanol (Fig. S1). Three days after adding methanol, a
band corresponding to the expected molecular weight for the
mapacalcine monomer appeared and remained present 5 days
after induction.
3.2. Puriﬁcation of 9HIS-mapacalcine
A large peak was eluted with 0.5 M imidazole from the IMAC
column (Fig. S2). WB and Coomassie analyses showed that a weak
band of less than 15 kDa was already detectable in the crude
culture medium. Analysis of the ﬂow-through demonstrated that
9HIS-mapacalcine was totally retained. No mapacalcine was elutedFig. 2. Puriﬁcation steps of 9HIS-mapacalcine. A: Elution proﬁle (280 nm) obtained dur
pools. B: SDS PAGE (Coomassie staining) and WB analyses of pools P1–P4. C: Chromatog
Vertical lines indicate the recombinant mapacalcine.during the wash step. Peak P eluted between 500 and 520 mL
corresponded to mapacalcine and very few mapacalcine was de-
tected in the peak shoulder Sh (520–540 mL).
The eluted material was loaded on the SEC column. Different
pools, P1–P4, were collected (Fig. 2A), analyzed by SDS PAGE and
WB (Fig. 2B). Coomassie staining of the SDS PAGE demonstrated
that P1 contained a single band corresponding to a strong signal in
WB with a MW around 15,000. Coomassie staining of P2 exhibited
a ﬁrst band at a MWaround 15,000 (close to the expected mass for
9HIS-mapacalcine) and a second one at a lower MW. The presence
of this larger band accounts for the discrepancy observed between
the signal in WB and the P1 and P2 optical densities. Fractions P3
and P4 did not exhibit bands in the Coomassie tracks and a very
faint or no signal in WB respectively. Fraction P1, corresponding to
a theoretical MW of 17 kDa according to column calibration, was
selected and submitted to C8 reverse phase puriﬁcation. The
chromatogram (Fig. 2C) showed a single peak, suggesting that the
purity of this fraction was suitable for further characterization and
biological assays.
3.3. Molecular weight determination by LSA
The Molecular weight of the 9HIS-mapacalcine was determined
by LSA which is a non-denaturing technology. Fig. S3 shows a
typical curve obtained when a sample of recombinant mapacalcine
is submitted to light scattering analysis. Data obtained exhibited a
MW of 16.1971.28 kDa (n¼32) which is in good agreement with
the molecular weight (17 kDa) theoretically determined as a
function of its elution volume from the SEC.
3.4. Removal of the ELWSPSY-9HIS-polyN peptide from mapacalcine.
After enzymatic cleavage and IMAC puriﬁcation of the reaction
mixture, SDS PAGE analysis of the ﬂow-through and eluted frac-
tions demonstrated that, regardless the enzyme used, no untagged
mapacalcine was eluted suggesting that the ELWSPSY-9HIS-PolyN
peptide was not removed (not shown). Therefore, we used 9HIS-
mapacalcine for subsequent experiments.
3.5. Mass spectrometry analyses
Mass spectrometry studies were performed to assess the integritying the size exclusion chromatography step. Vertical lines delimitate the different
ram (280 nm) obtained after injection of pool P1 on the C8 reverse phase column.
Fig. 3. ESI-MS analysis of 9HIS-mapacalcine. Deconvoluted spectra and zooms on regions of interest. 9HIS-mapacalcine was analyzed after different treatments: A: Un-
treated. B: treated with DTT. C: treated with iodoacetamide.
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and to evaluate the number of disulﬁde bonds. Electrospray ioniza-
tion (ESI)-MS demonstrated the presence of two major forms at
14,445 and 15,144 Da (Fig. 3A). None of them corresponded to the
theoretical mass of the recombinant monomeric protein calculated
from the sequence (14,848 Da, taking into account all disulﬁde bonds
in reduced form).
When a reducing treatment with DTT was applied, the mass of
the two major peaks shifted to [MþH]þ values of 14,142 and
14,842 Da (Fig. 3B). The highest mass matched the expected the-
oretical mass of a mapacalcine monomer bearing three to four
residual disulﬁde bonds (among the four possible ones). These
results are in good agreement with earlier observations on native
mapacalcine indicating that disulﬁde bonds are difﬁcult to reduce
(unpublished data).
With or without reduction step, the mass difference between
both peaks was unchanged (70071 Da). In each experiment, the
lower mass was consistent with the elimination of the six ﬁrst
N-terminal amino acids (ELWSPS). Such an event is commonly
encountered for heterologous expression of recombinant proteins
in P. pastoris [13,14]. The mass shift observed for each peak after
reduction (302 and 303 Da) was identical, within the mass toler-
ance, indicating that these two forms bore the same modiﬁcation,
probably a glutathione. Four satellite peaks were detected for each
form (Fig. 3A). Peaks at respectively 14,542 and 15,242 Da ex-
hibiting a mass difference of þ98 Da (72) may correspond to a
phosphate adduct. The three others, (black stars), cannot be ex-
plained by protein cleavage. As they disappear after treatment
with DTT (Fig. 3B) they may correspond to uncharacterized ad-
ducts to a cysteine. Moreover, these additional forms cannot be
due to deconvolution errors of ESI-MS spectra as at least two of
them are detected by MALDI-MS analysis (Fig. S4).
Since no representative peak corresponding to a dimer was
found by the software used to deconvoluate the ESI-MS spectra(Fig. 3A), these data suggested that the recombinant mapacalcine
was a monomer. This result was conﬁrmed by MALDI-MS which
clearly showed the absence of dimer in the appropriate 29–30 kDa
mass range (Fig. S4A).
Detection of possible free cysteines was achieved by IAA
treatment, used as protein alkylating agent, followed by ESI-MS.
No mass shift was observed (Fig. 3C), indicating that all cysteine
sulfhydryl functions were blocked, suggesting that four disulﬁde
bonds are formed and that the ninth cysteine does not react.
The IAA treatment, conducted on the reduced protein, led to
two additional major peaks at 14,899 Da and 14,199 Da (data not
shown), each showing a mass difference of 57 Da compared to the
full-length mapacalcine and its degradation product (14,842 Da
and 14,142 Da, respectively). This mass shift (in agreement with
the binding of one unique IAA) demonstrates that the DTT treat-
ment only eliminated the 30271 Da modiﬁcation bore by one
cysteine. Nevertheless, the presence of minor peaks observed for
each protein (at þ114 Da, þ171 Da etc.) indicated that species
with more than one IAA were present suggesting that disulﬁde
bonds can be partially cleaved by the reducing treatment.
3.6. Protective effects of 9HIS-mapacalcine against hypoxia
We studied the protective role of 9HIS-mapacalcine using the
OGD protocol, which is considered as the best reliable in vitromodel
for ischemia [15,16]. Effects of 9HIS-mapacalcine were compared to
those of the native mapacalcine. OGD consists in a glucose and
oxygen deprivation, 1.2% instead of 5% O2 in normal conditions. Ten
to twelve days aged mouse cortical neurons were submitted to OGD
in the presence or absence of 1 mM 9HIS-mapacalcine or 1 mM na-
tive mapacalcine. After 2 h of OGD, the number of surviving cells
was counted in nine 0.38 mm2 ﬁelds randomly selected by a com-
puter in each of six Petri dishes. It clearly appeared that 9HIS-ma-
pacalcine as well as native mapacalcine increased cell survival
Fig. 4. Effects of 9HIS-mapacalcine and native mapacalcine on cortical neurons during OGD. A: Results were expressed as the mean value of cells per mm2 7 SEM.
Incubations were performed in the absence (Control) or in the presence of 1mM of 9HIS-mapacalcine (9-His mapa), or 1 mm of native mapacalcine (Nat mapa), ***po0.005
(Student t-test). B: Typical pictures of one counted ﬁeld in control, 9HIS-mapacalcine and native mapacalcine conditions. C: Comparison of effects of 1 mM of 9HIS-ma-
pacalcine or native mapacalcine on electrophysiological recordings in cortical neurons. The holding potential was 80 mV. Calcium currents were recorded from 70 to
þ50 mV in control condition (●), in the presence of 9HIS-mapacalcine ( ) or native mapacalcine ( ). In each condition, current densities (pA/pF) are shown as a function of
membrane potential (mV). Bars represent the SEM values, n¼10 for each condition, po0.05. D: Basal calcium levels. The ﬂuorescence intensity of a calcium indicator Fluo-2/
AM was measured in the absence (Control) or in the presence of 1 mM of 9HIS-mapacalcine (9-His mapa) or native mapacalcine (Nat mapa). Results are means 7 SEM of
6 independent dishes, ***po 0.005 (Student t-test).
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for 9HIS-mapacalcine and native mapacalcine versus control, re-
spectively (Fig. 4A and B). These results showed that 9HIS-mapa-
calcine acts as a protective agent against ischemia. This protective
effect is strengthened by the fact that 9HIS-mapacalcine (1 mM), as
native mapacalcine, was able to block a calcium current recorded on
cortical neurons (Fig. 4C) and to reduce the calcium inﬂux in basal
conditions (Fig. 4D). The increase of intracellular calcium con-
centration is a major event that contributes to neuron death fol-
lowing an ischemic insult [17]. Taken together, these data evidencethat the monomeric 9HIS-mapacalcine retains the same properties
as the native mapacalcine [12].4. Discussion
Disulﬁde bonds are a typical feature of secreted proteins. They
often play a crucial role in the folding leading to the functionally
active form of a protein. As the difﬁculty to reach the native con-
formation increases with the number of cysteine residues yielding
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systems have been used or designed to successfully produce dis-
ulﬁde-rich proteins. For that purpose, engineered strains like Or-
igami or Shufﬂe have been developed in Escherichia coli, and in
vitro expression systems tested [18–20]. As far as we know, the
protein containing the highest number of disulﬁde bridges ex-
pressed in E. coli is resistin (11 cysteine residues, 108 aminoacids)
[21]. Nevertheless, using such expression systems, we only ob-
tained an insoluble form of recombinant mapacalcine suggesting
that it was misfolded. Many proteins containing intra- or inter-
molecular disulﬁde bridges have been successfully expressed in P.
pastoris [22,23], such as Pisum sativum defensin (8 cysteines, 47
aminoacids) [24], human α-defensin 5 (6 cysteines, 32 aminoa-
cids) [25], and human hepcidin-25 (8 cysteines, 25 aminoacids)
[26]. The highest cysteine containing protein expressed in P. pas-
toris is the secretory leukocyte protease inhibitor (16 cysteines, 107
aminoacids) [27]. We tried thus to express mapacalcine in P. pas-
toris. Data presented here demonstrate that P. pastoris produces a
soluble and biologically active recombinant mapacalcine in rea-
sonable amounts (5 mg of protein/L of culture medium).
Neither TEV protease nor EK was able to cleave the N-terminal
part of the recombinant mapacalcine. This observation suggests
that the enzyme cleavage site is probably embedded in the mo-
lecule while the 9HIS tag (or part of it), located 15 aminoacids
farther toward the N-terminus of the molecule (see Fig. 1B), can
interact with the Ni-NTA column. In all biological assays the pre-
sence of the ELWSPSY-9HIS-polyN-EK-TEV peptide did not modify
the biological activity of the recombinant mapacalcine with re-
spect to the activity of native mapacalcine suggesting that it does
not bear residual activity. Whereas chromatographic data obtained
after the C8 puriﬁcation step (Fig. 2C) only demonstrated a single
peak, mass spectrometry analyses revealed the presence of two
9HIS-mapacalcine monomeric forms. A possible explanation is
that mass spectrometry only provides qualitative but not quanti-
tative results. However the deleted aminoacids which character-
ized one form with respect to the other cannot be easily proto-
nated. Thus, it is unlikely that such a modiﬁcation alters sig-
niﬁcantly the ionization of each species and consequently the re-
spective intensity of their peaks. Another explanation would be
that these aminoacids poorly interfere with the C8 column so that
they might have no noticeable impact on both species retention
time.
We cannot determine if both forms are biologically active as we
were unable to separate them. Nevertheless, several points are to
be considered. Firstly, the 6 aminoacids deleted at the N-terminal
position do not belong to the sequence of the natural mapacalcine.
Moreover, these aminoacids are located 44 residues before the
native mapacalcine sequence and have poor chances to disturb its
folding, especially because it is stiffened by the four disulﬁde
bridges. We then assume that both forms may present a rather
similar activity.
Native mapacalcine has been described as a dimer linked by at
least one disulﬁde bridge [7]. We also detected it as a dimer by
dissociating mass spectrometry like MALDI-TOF before DTT treat-
ment and as a monomer after DTT treatment, conﬁrming that the
dimer was linked by at least one disulﬁde bridge (not shown). The
recombinant mapacalcine was detected as a monomer by the same
technique. Gentle technics like LSA an SEC demonstrated a mole-
cular weight consistent with a monomer. Taken together, these
observations suggest that no dimeric form of mapacalcine even
linked by non-covalent interactions was produced. The presence of
a 300 Da molecular entity bound to a free cysteine is consistent
with the idea that this unpaired cysteine may be modiﬁed by a
glutathione, a current feature in protein production in P. pastoris
when methanol is used as inducer [28,29]. This may explain why
only the monomeric form of the protein is obtained. All the othercysteines being engaged in intramolecular bridges, the ninth cy-
steine (theoretically unpaired) of two different monomers cannot
react together to form a dimer. When using an enzymatic deglu-
tathionylation to selectively remove such an entity while preser-
ving the disulﬁde bridges, we failed to clearly evidence the pre-
sence of a glutathione (data not shown). This may indicate that the
concerned cysteine remains inaccessible to enzymes. Further
productions, avoiding the presence of inducers such as methanol,
are actually in progress. Nevertheless, the recombinant mono-
meric mapacalcine production described in this work provides a
convenient tool for further applications such as receptor identiﬁ-
cation, immuno-histology, anti-ischemic applications. The fact that
it has similar biological properties as the natural (dimeric) ma-
pacalcine suggests (i) that the tertiary structure of the monomer of
recombinant mapacalcine is probably similar to the one of the
native protein, the formation of the dimer being prevented by the
blocking of the cysteine by a glutathione. (ii) That it retains the
essential structural domains required for its activity. These prop-
erties evidence its usefulness to conduct site directed mutagenesis
and therefore to identify the minimum pattern responsible for the
biological activity of the protein.Acknowledgements
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